Improvement of health-related quality of life and adherence to treatment with calcipotriol-betamethasone dipropionate gel in patients with psoriasis vulgaris

Abstract BACKGROUND: Psoriasis is a common, chronic, recurrent, immune-mediated disorder of the skin and joints. It can have a significant negative impact on the physical, emotional and psychosocial wellbeing of affected patients. OBJECTIVES: To measure improvement in health-related QoL (HRQoL) in G...

Full description

Saved in:
Bibliographic Details
Main Authors: George Kontochristopoulos (Author), Anargyros Kouris (Author), Athanasios Chantzaras (Author), Athanasios Petridis (Author), John Yfantopoulos (Author)
Format: Book
Published: Sociedade Brasileira de Dermatologia, 2016-04-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_a67b86b52e7e488a9d409569e2e5b5e4
042 |a dc 
100 1 0 |a George Kontochristopoulos  |e author 
700 1 0 |a Anargyros Kouris  |e author 
700 1 0 |a Athanasios Chantzaras  |e author 
700 1 0 |a Athanasios Petridis  |e author 
700 1 0 |a John Yfantopoulos  |e author 
245 0 0 |a Improvement of health-related quality of life and adherence to treatment with calcipotriol-betamethasone dipropionate gel in patients with psoriasis vulgaris 
260 |b Sociedade Brasileira de Dermatologia,   |c 2016-04-01T00:00:00Z. 
500 |a 0365-0596 
500 |a 10.1590/abd1806-4841.20164476 
520 |a Abstract BACKGROUND: Psoriasis is a common, chronic, recurrent, immune-mediated disorder of the skin and joints. It can have a significant negative impact on the physical, emotional and psychosocial wellbeing of affected patients. OBJECTIVES: To measure improvement in health-related QoL (HRQoL) in Greek patients with psoriasis vulgaris after a month of treatment with calcipotriol-betamethasone dipropionate gel; and evaluate adherence to treatment parameters. METHODS: The study included 394 psoriasis vulgaris patients from 16 private dermatological practices in Greece, all treated with calcipotriol-betamethasone dipropionate gel. They were evaluated at the first visit and after 4 weeks. Moreover, they completed the Dermatology Life Quality Index (DLQI), while other data such as disease severity, subjective symptoms and adherence, were collected. RESULTS: At week 4, the DLQI median was reduced by 3.5 points from the baseline (p<0.001; baseline and week 4 median: 4.5 and 1.0 respectively). Pruritus and sleep disorders also improved (p<0.001). Furthermore, 90.1% of the subjects fully adhered to treatment, with a 97.1% mean level of compliance. CONCLUSIONS: The convincing clinical results, with a distinct improvement in HRQoL, plus the high level of adherence due to its advantageous physical properties, make the calcipotriol-betamethasone dipropionate gel formulation an important, effective and well-tolerated topical therapy to treat psoriasis. 
546 |a EN 
546 |a PT 
690 |a Indicators of quality of life 
690 |a Psoriasis 
690 |a Quality of life 
690 |a Dermatology 
690 |a RL1-803 
655 7 |a article  |2 local 
786 0 |n Anais Brasileiros de Dermatologia, Vol 91, Iss 2, Pp 160-166 (2016) 
787 0 |n http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0365-05962016000200160&tlng=en 
787 0 |n http://www.scielo.br/pdf/abd/v91n2/0365-0596-abd-91-02-0160.pdf 
787 0 |n https://doaj.org/toc/0365-0596 
856 4 1 |u https://doaj.org/article/a67b86b52e7e488a9d409569e2e5b5e4  |z Connect to this object online.